Skip to main content
. 2021 Jan 1;11(2):540–554. doi: 10.7150/thno.49517

Figure 7.

Figure 7

HT40 increased melanoma specific antitumor immunity. (A) A significant increase in CD44hi CD62lo CD4+ effector T memory cells (percentage out of total leukocytes) in HT and HT40 treated tumors was noted. (B and C) αCD40 and HT40 enhanced the percent of M1 macrophages by 2-fold and decreased M2 macrophages by 1.5-fold compared to controls. (D and E) HT, αCD40 and HT40 increased M1 macrophages (~1.3-1.7-fold) and decreased M2 macrophages (~1.5-2-fold) in splenic tissues compared to the control. (F) IL-2 production from CD4+ T cells was significantly improved by αCD40 and HT40 treatments compared to untreated controls. Amongst all the treatments, HT40 showed the most dominant effect upon TRP-2 stimulation ex-vivo. Data are shown as mean ± SEM, n=3-5 per group. Data were analyzed by ANOVA followed by Tukey's multiple comparisons. * p < 0.05, ** p < 0.01.